The U.S. Food and Drug Administration (FDA) on Sept. 26 approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for treating adult patients with schizophrenia. The move represents the first new class of treatment for this population in three decades.
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: